Carisoprodol

證據等級: L5

預測適應症: 1 個

CARISOPRODOL: From Musculoskeletal Pain to Insomnia

One-Sentence Summary

Carisoprodol is a centrally-acting skeletal muscle relaxant, traditionally used for relief of acute musculoskeletal pain and spasm. The TxGNN model predicts it may be effective for Insomnia, with 0 clinical trials and 1 publication currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Skeletal muscle relaxant (musculoskeletal pain / spasm)
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.02%
Evidence Level	L4
Market Status	Not marketed
Number of Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Carisoprodol is a centrally-acting skeletal muscle relaxant whose therapeutic and sedative effects are largely mediated through its primary metabolite, meprobamate — a GABA-A receptor positive modulator with CNS depressant, sedative, and anxiolytic properties. In theory, this pharmacological profile could shorten sleep-onset latency and prolong total sleep time, the two principal targets of insomnia pharmacotherapy.

A second, indirect pathway also exists: by relieving nocturnal muscle cramps, carisoprodol may reduce nighttime awakenings and thereby improve sleep continuity. This mechanism is consistent with the single identified publication, which documents nocturnal leg cramps as a recognized cause of severe insomnia in up to 60% of affected adults.

However, the same GABA-A modulation that could promote sleep is inseparable from carisoprodol’s well-documented dependence liability (via meprobamate). This substantially narrows the therapeutic window and makes carisoprodol unsuitable as a first-line or repurposing candidate for insomnia without considerably more controlled evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22963024	2012	Clinical Review	American Family Physician	Up to 60% of adults report nocturnal leg cramps; severe insomnia is a recognized consequence of recurrent calf-muscle tightening, supporting the hypothesis that muscle relaxation may improve sleep continuity.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence base consists of a single indirect clinical review with no mechanism specific to insomnia and zero registered clinical trials; simultaneously, carisoprodol’s metabolite meprobamate carries a high addiction and dependence risk that substantially outweighs any theoretical sleep benefit.

To proceed, the following is needed:

Full mechanism of action (MOA) data from DrugBank or peer-reviewed pharmacology references to strengthen the mechanistic rationale
Package insert safety data including warnings, contraindications, and drug-drug interactions (currently unavailable)
At minimum one prospective observational study or Phase 2 trial specifically investigating carisoprodol or meprobamate for insomnia
Assessment of controlled-substance / scheduling status in the target jurisdiction, given widespread regulatory restrictions on carisoprodol due to abuse potential
Risk-benefit analysis comparing carisoprodol against approved insomnia agents (e.g., non-benzodiazepine hypnotics, doxepin) to justify further development
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.